查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1992953

癌症生技藥品市場：2026-2032年全球市場預測（依產品類型、癌症類型、最終用戶和通路分類）

Cancer Biologics Market by Product Type, Cancer Type, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025年癌症生技藥品市值為1,088.8億美元，預計到2026年將成長至1,165.8億美元，複合年成長率為6.59%，到2032年將達到1,703億美元。

主要市場統計數據
基準年 2025 1088.8億美元
預計年份：2026年 1165.8億美元
預測年份 2032 1703億美元
複合年成長率 (%) 6.59%

癌症生物製劑領域中影響策略決策的科學進步、監管複雜性和商業性需求的關鍵背景資訊。

癌症生物製劑領域正處於一個十字路口，科學突破、不斷演變的法規結構和商業模式在此交匯融合。免疫腫瘤學、細胞和基因療法以及精準標靶生技藥品的最新進展，在拓展治療可能性的同時，也增加了計畫的複雜性。因此，產品開發路徑如今需要更深入的轉化證據、更具適應性的臨床試驗設計，以及監管、生產和商業部門之間的早期協作。本文旨在建構一個將臨床創新與實際商業需求結合的整合管理觀點。

重新定義癌症生技藥品的發展路徑和策略挑戰：技術、商業和醫療保健服務的關鍵變革的融合。

生技藥品領域正經歷著一場變革性的轉型，其驅動力包括技術成熟、資金籌措模式的轉變以及患者期望的不斷提高。在技​​術層面，細胞療法和基因編輯技術正從概念驗證（PoC）階段邁向迭代最佳化階段，優先考慮安全性、可生產性和持續療效。同時，儘管雙特異性抗體和抗體藥物複合體（ADC）正在拓展治療的邊界，但單株抗體仍然是標靶治療的基石。這些治療方法的轉變促使申辦方重新評估其研發時間表，並投資於支援快速迭代開發的平台能力。

2025 年美國關稅調整對採購、製造、物流和長期商業化規劃的策略影響。

2025年宣布的關稅政策調整的累積影響，正在美國進口和出口的生技藥品的採購、生產和分銷的各個環節帶來新的變數。關稅調整可能會改變原料、組件和成品生技藥品生產地點的判定標準，促使企業重新審視其供應商組合，並對關鍵投入品實施雙重採購以降低風險。同時，不斷上漲的進口成本也凸顯了本地生產投資以及與國內合約研發生產力機構（CDMO）建立策略夥伴關係的重要性，以維持供應鏈的連續性和成本的可預測性。

將治療方法、癌症適應症、終端用戶趨勢和分銷管道與業務運營和商業策略聯繫起來的基於詳細細分的洞察。

按細分市場了解癌症生技藥品市場，有助於揭示科學機會、商業性可行性和營運複雜性之間的交匯點。按產品類型分類，該市場涵蓋癌症疫苗、細胞療法、基因療法、單株抗體和重組蛋白。在單株抗體領域，抗CD20、抗HER2、抗PD-1/PD-L1和抗VEGF等成熟類別持續影響臨床策略，而Obinutuzumab、利妥昔單抗、Rituximab、曲Pertuzumab珠單抗、阿特珠單抗、納AtezolizumabNivolumab和Bevacizumab等個別藥物定位和生命週期的抗定位。這種詳細的產品層面分析突顯了在生產複雜性、低溫運輸物流和監管證據方面的不同需求。

區域間在臨床能力、法規結構和生產能力的差異，會影響市場進入和商業化策略。

區域趨勢對癌症生技藥品的整體研發策略、監管合作和商業化路徑有顯著影響。在美洲，先進的臨床生態系統、以支付主導的證據要求以及完善的生產基礎設施，既帶來了機遇，也帶來了挑戰。在該地區運作的相關人員必須平衡強力的臨床證據的獲取、與支付方的溝通以及供應鏈的柔軟性。在歐洲、中東和非洲（EMEA），不同的法規環境和報銷框架要求企業採取因地制宜的市場進入策略和區域性定價策略。與區域分銷商建立策略夥伴關係關係對於應對報銷和監管方面的細微差異至關重要。

主要企業如何重組其研發、製造和商業職能部門的能力，以保持創新並縮短產品上市時間。

腫瘤生物製劑領域的主要企業正透過對平台技術的策略性投資、擴大生產能力以及建立協作生態系統來應對日益複雜的挑戰。許多機構正在採用整合開發模式，儘早將臨床、監管和生產方面的相關人員聚集在一起，從而降低規模化生產的風險並加快跨職能決策。策略聯盟、授權和定向收購是獲取細胞療法生產、基因載體生產和生物標記主導開發所需先進分析能力的常用手段。

制定可操作的策略重點，以協調臨床創新、生產韌性、支付方參與和通路特定商業化，實現永續成長。

產業領導者應優先考慮如何使科學研究機會與商業可行性及支付方預期相契合。首先，從早期專案階段就將臨床開發與可擴展的生產方案結合，可以減少後續環節的延誤，並加速向商業化供應的過渡。企業應考慮採用模組化和分散式生產方式，作為風險分散型生產策略的一部分，以減少供應鏈中的單點故障。其次，早期投資於真實世界數據（REW）的生成和衛生經濟學能力建設，將有助於加強與支付方的溝通，並促進建立更可預測的准入途徑。

結合與關鍵相關人員的對話、可靠的二手資料和情境分析的調查方法，確保了可靠且可操作的見解。

本研究採用系統性的調查方法，整合一手與二手訊息，旨在兼顧深入洞察與實際應用。一手資訊包括對臨床負責人、生產專家、支付方和分銷合作夥伴的結構化訪談，以及匿名化的醫療專業人員問卷調查，以了解實際挑戰和新興實踐。二手資訊包括同行評審文獻、監管指南、臨床試驗註冊數據和上市公司文件，以檢驗趨勢並根據臨床和商業性管道對產品原型進行分類。

結論整合了科學潛力、實際情況以及將創新轉化為永續的臨床和商業性成功所需的策略行動。

總之，癌症生技藥品已進入一個階段，在這個階段，科學潛力必須與嚴謹的運作和戰略遠見結合。儘管細胞療法和基因療法等突破性治療方法，以及單株抗體製劑的不斷發展，正在創造廣泛的治療可能性，但要成功地將這些療法轉化為對患者的益處，整合開發、生產和商業化流程至關重要。那些積極開展跨職能團隊合作、投資穩健的供應鏈並建立以支付觀點的循證策略的機構，最有能力將科學進步轉化為永續的臨床和商業性成功。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 癌症生技藥品市場：依產品類型分類

  • 癌症疫苗
  • 細胞療法
  • 基因治療
  • 單株抗體
    • 抗CD20
      • Obinutuzumab
      • Rituximab
    • 抗HER2
      • Pertuzumab
      • 曲妥珠單抗
    • 抗PD-1/PD-L1
      • Atezolizumab
      • Nivolumab
      • Pembrolizumab
    • 抗 VEGF
  • 重組蛋白

第9章：以癌症類型分類的癌症生技藥品市場

  • 乳癌
  • 結腸癌
  • 骨髓惡性腫瘤
  • 肺癌
  • 惡性黑色素瘤
  • 攝護腺癌

第10章 癌症生技藥品市場：依最終用戶分類

  • 門診手術中心
  • 居家醫療設施
  • 醫院和診所
  • 腫瘤中心

第11章 癌症生技藥品市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章生技藥品市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 癌症生技藥品市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章生技藥品市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國癌症生技藥品市場

第16章：中國癌症生技藥品市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • ADC Therapeutics SA
  • Agenus Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Autolus Therapeutics plc
  • BeiGene, Ltd.
  • Biocon Limited
  • BioNTech SE
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Modex Therapeutics AG
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Seagen Inc.
Product Code: MRR-1A1A064C014D

The Cancer Biologics Market was valued at USD 108.88 billion in 2025 and is projected to grow to USD 116.58 billion in 2026, with a CAGR of 6.59%, reaching USD 170.30 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 108.88 billion
Estimated Year [2026] USD 116.58 billion
Forecast Year [2032] USD 170.30 billion
CAGR (%) 6.59%

Essential contextual framing of scientific advances, regulatory complexity, and commercial imperatives shaping strategic decision-making in cancer biologics

The cancer biologics domain is at an inflection point where scientific breakthroughs converge with shifting regulatory frameworks and evolving commercial models. Recent advances in immuno-oncology, cell and gene modalities, and precision-targeted biologics have expanded therapeutic possibilities while simultaneously elevating program complexity. As a result, product development pathways now demand deeper translational evidence, adaptive clinical designs, and earlier alignment across regulatory, manufacturing, and commercial functions. This introduction sets the stage for an integrated executive view that ties clinical innovation to pragmatic business imperatives.

Throughout this document, stakeholders will find synthesized insights intended to support strategic planning, portfolio prioritization, and partnership decisions. The goal is to present a cohesive narrative that balances scientific potential with operational realities, helping leaders anticipate trade-offs between speed to clinic, scale-up risk, and payer engagement. By framing opportunities alongside common constraints, this introduction prepares decision-makers to interpret the subsequent sections with clarity and purpose.

Pivotal technological, commercial, and care-delivery transformations converging to redefine development pathways and strategic imperatives across cancer biologics

The landscape of cancer biologics is undergoing transformative shifts driven by technological maturation, shifting financing models, and evolving patient expectations. On the technological front, cell therapies and gene editing techniques are moving from proof-of-concept toward iterative optimization that prioritizes safety, manufacturability, and durability of response. At the same time, monoclonal antibodies remain a backbone of targeted therapy, even as bispecific formats and antibody-drug conjugates push therapeutic boundaries. These modality-driven changes are causing sponsors to re-evaluate R&D timelines and to invest in platform capabilities that support rapid iteration.

Commercially, payer scrutiny and value-based contracting are driving earlier evidence generation focused on real-world effectiveness and health economics. Partnerships between biopharma companies, contract manufacturers, and specialty service providers are also deepening to address capacity constraints and reduce time-to-treatment. Moreover, patient-centric care models, including home-based administration and decentralized trials, are reshaping distribution and delivery strategies. Together, these shifts require companies to be more agile in aligning clinical development with commercial and supply chain strategies, while maintaining a relentless focus on safety and evidence quality.

Strategic implications of United States tariff adjustments in 2025 on sourcing, manufacturing, logistics, and long-term commercialization planning

The cumulative effects of tariff policy changes announced for 2025 have introduced new variables across sourcing, manufacturing, and distribution for cancer biologics entering or leaving the United States. Tariff adjustments can alter the calculus for where raw materials, components, and finished biologics are manufactured, prompting companies to reassess supplier portfolios and dual-source critical inputs to reduce exposure. In parallel, increased import costs can raise the importance of localized manufacturing investments and strategic partnerships with domestic contract development and manufacturing organizations to preserve supply chain continuity and cost predictability.

Beyond near-term sourcing decisions, tariff dynamics influence long-range planning for capital investments, pricing strategies, and contractual terms with distributors and payers. Companies managing global clinical programs may face administrative burdens linked to customs classification and compliance, which can lengthen lead times and complicate logistics planning. Consequently, commercial teams must work closely with regulatory, legal, and procurement functions to model tariff scenarios, renegotiate supplier agreements where feasible, and prioritize modular manufacturing approaches that enable incremental capacity expansion without excessive fixed-cost commitments.

Deep segmentation-driven insights linking modality, cancer indication, end-user dynamics, and distribution channels to operational and commercial strategy

Segmented understanding of the cancer biologics market illuminates where scientific opportunity intersects with commercial viability and operational complexity. When considered by product type, the market spans cancer vaccines, cell therapy, gene therapy, monoclonal antibodies, and recombinant proteins; within monoclonal antibodies, established classes such as Anti-CD20, Anti-HER2, Anti-PD-1/PD-L1, and Anti-VEGF continue to shape clinical strategies, and individual agents like Obinutuzumab, Rituximab, Pertuzumab, Trastuzumab, Atezolizumab, Nivolumab, Pembrolizumab, and Bevacizumab serve as reference points for competitive positioning and lifecycle management. This product-level granularity highlights differing demands around manufacturing complexity, cold-chain logistics, and regulatory evidence.

When analyzed through the lens of cancer type, distinctions among breast cancer, colorectal cancer, hematological malignancies, lung cancer, melanoma, and prostate cancer clarify patient population dynamics and therapeutic endpoints, which in turn inform trial design and commercialization focus. End-user segmentation-spanning ambulatory surgery centers, homecare settings, hospitals and clinics, and specialized oncology centers-reveals varied administration pathways and reimbursement touchpoints, creating differentiated service and distribution models. Finally, distribution channel segmentation across hospital pharmacies, online pharmacies, retail pharmacies, and specialty distributors underscores the importance of channel-specific strategies for patient access, adherence support, and supply chain resilience, and it encourages targeted commercial models that reflect each channel's regulatory and operational realities.

Regional variations in clinical capacity, regulatory frameworks, and manufacturing capabilities that shape tailored market entry and commercialization strategies

Regional dynamics materially influence development strategies, regulatory interactions, and commercialization pathways across cancer biologics. In the Americas, a combination of advanced clinical ecosystems, payer-driven evidence requirements, and a strong manufacturing base creates both opportunity and complexity; stakeholders operating here must align robust clinical evidence generation with payer engagement and supply chain flexibility. Europe, Middle East & Africa present heterogeneous regulatory environments and reimbursement frameworks where adaptive market entry tactics and localized pricing strategies are essential, and strategic partnerships with regional distributors are often critical to navigate reimbursement and regulatory nuances.

Asia-Pacific markets exhibit a mix of large patient populations and rapidly expanding clinical trial capacity, accompanied by rising domestic capabilities in biologics manufacturing. Companies engaging in this region frequently balance accelerated enrollment advantages with the need for tailored evidence packages and supply chain adaptations to meet local regulatory expectations. Taken together, these regional vectors require nuanced approaches to clinical strategy, manufacturing footprint decisions, and commercialization planning that reflect both macroeconomic conditions and country-level regulatory idiosyncrasies.

How leading organizations are reshaping capabilities across R&D, manufacturing, and commercial functions to sustain innovation and improve time-to-market

Leading companies in the cancer biologics arena are responding to heightened complexity through strategic investments in platform technologies, expanded manufacturing capacity, and collaborative ecosystems. Many organizations are adopting integrated development models that bring clinical, regulatory, and manufacturing stakeholders together earlier to de-risk scale-up and accelerate cross-functional decision-making. Strategic alliances, licensing arrangements, and targeted acquisitions are common tools used to secure capabilities in cell therapy manufacturing, gene vector production, and advanced analytics for biomarker-driven development.

Operationally, firms are prioritizing supply chain resiliency by diversifying suppliers, qualifying alternate fill-finish partners, and investing in cold-chain infrastructure. On the commercial side, companies are expanding capabilities in real-world data generation and value demonstration to better position biologics with payers and health systems. Talent strategies are also evolving, with leaders recruiting cross-disciplinary teams capable of navigating regulatory complexity while optimizing manufacturing throughput and patient access initiatives. Collectively, these company-level moves indicate a shift toward more integrated, risk-aware operations that can sustain both innovation and commercialization at scale.

Actionable strategic priorities to align clinical innovation, manufacturing resilience, payer engagement, and channel-specific commercialization for sustainable growth

Industry leaders should prioritize actions that align scientific opportunity with operational viability and payer expectations. First, aligning clinical development with scalable manufacturing considerations from early-phase programs will reduce downstream delays and support faster transitions into commercial supply. Companies should consider modular and distributed manufacturing approaches as part of a hedged capacity strategy to reduce single-point failures in the supply chain. Second, investing in real-world evidence generation and health economics capabilities early will strengthen payer conversations and facilitate more predictable access pathways.

Third, leaders should actively pursue strategic partnerships to fill capability gaps-whether in viral vector production, cell therapy logistics, or regulatory intelligence-rather than attempting full vertical integration for every modality. Fourth, companies must develop differentiated channel strategies that reflect administration settings, from homecare to specialized oncology centers, ensuring that patient support, adherence programs, and reimbursement navigation are tailored to each channel. Finally, scenario planning that incorporates tariff volatility, geopolitical risks, and rapid technological shifts will enable more resilient capital allocation and portfolio decisions.

Methodological approach combining primary stakeholder engagement, authoritative secondary sources, and scenario analysis to ensure robust, actionable insights

This research synthesizes primary and secondary intelligence through a structured methodology designed to balance depth of insight with practical applicability. Primary inputs included structured interviews with clinical leaders, manufacturing experts, payers, and distribution partners, complemented by anonymized practitioner surveys to capture operational pain points and emergent practices. Secondary inputs drew on peer-reviewed literature, regulatory guidance, clinical trial registries, and company-published materials to validate trends and to map product archetypes against clinical and commercial pathways.

Analytical approaches combined qualitative thematic synthesis with scenario analysis to stress-test strategic implications under varied regulatory, tariff, and supply chain conditions. Cross-validation steps included expert review panels and iterative triangulation of findings across data sources to ensure robustness. The result is a reproducible framework that links modality characteristics, disease indication nuances, end-user requirements, and channel dynamics to actionable strategic recommendations.

Concluding synthesis tying together scientific potential, operational realities, and strategic actions required to translate innovation into sustained clinical and commercial success

In conclusion, cancer biologics are entering a phase where scientific possibility must be matched by operational rigor and strategic foresight. Breakthrough modalities such as cell and gene therapies and the continued evolution of monoclonal antibody formats create expansive therapeutic potential, but their successful translation into patient impact depends on integrated approaches to development, manufacturing, and commercialization. Organizations that proactively align cross-functional teams, invest in resilient supply chains, and cultivate payer-aligned evidence strategies will be best positioned to convert scientific advances into sustained clinical and commercial success.

Moving forward, leaders will need to treat strategic planning as a dynamic capability-one that iterates with new data, regulatory signals, and market feedback. By embracing modular manufacturing, targeted partnerships, and differentiated channel strategies, companies can navigate complexity while accelerating patient access to transformative biologics. The balance of innovation and operational excellence will determine which organizations convert opportunity into durable therapeutic impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cancer Biologics Market, by Product Type

  • 8.1. Cancer Vaccines
  • 8.2. Cell Therapy
  • 8.3. Gene Therapy
  • 8.4. Monoclonal Antibodies
    • 8.4.1. Anti-CD20
      • 8.4.1.1. Obinutuzumab
      • 8.4.1.2. Rituximab
    • 8.4.2. Anti-HER2
      • 8.4.2.1. Pertuzumab
      • 8.4.2.2. Trastuzumab
    • 8.4.3. Anti-PD-1/PD-L1
      • 8.4.3.1. Atezolizumab
      • 8.4.3.2. Nivolumab
      • 8.4.3.3. Pembrolizumab
    • 8.4.4. Anti-VEGF
  • 8.5. Recombinant Proteins

9. Cancer Biologics Market, by Cancer Type

  • 9.1. Breast Cancer
  • 9.2. Colorectal Cancer
  • 9.3. Hematological Malignancies
  • 9.4. Lung Cancer
  • 9.5. Melanoma
  • 9.6. Prostate Cancer

10. Cancer Biologics Market, by End User

  • 10.1. Ambulatory Surgery Centers
  • 10.2. Homecare Settings
  • 10.3. Hospitals & Clinics
  • 10.4. Oncology Centers

11. Cancer Biologics Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Cancer Biologics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Cancer Biologics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Cancer Biologics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Cancer Biologics Market

16. China Cancer Biologics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc.
  • 17.6. ADC Therapeutics SA
  • 17.7. Agenus Inc.
  • 17.8. Amgen Inc.
  • 17.9. AstraZeneca PLC
  • 17.10. Autolus Therapeutics plc
  • 17.11. BeiGene, Ltd.
  • 17.12. Biocon Limited
  • 17.13. BioNTech SE
  • 17.14. Bristol-Myers Squibb Company
  • 17.15. F. Hoffmann-La Roche Ltd.
  • 17.16. GlaxoSmithKline plc
  • 17.17. Johnson & Johnson
  • 17.18. Merck & Co., Inc.
  • 17.19. Modex Therapeutics AG
  • 17.20. Novartis AG
  • 17.21. Pfizer Inc.
  • 17.22. Regeneron Pharmaceuticals, Inc.
  • 17.23. Sanofi S.A.
  • 17.24. Seagen Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANCER BIOLOGICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CANCER BIOLOGICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES CANCER BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA CANCER BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CANCER BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY OBINUTUZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY OBINUTUZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY OBINUTUZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY RITUXIMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY RITUXIMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY RITUXIMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY PERTUZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY PERTUZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY PERTUZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY TRASTUZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY TRASTUZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY TRASTUZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ATEZOLIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ATEZOLIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY NIVOLUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY NIVOLUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY PEMBROLIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY PEMBROLIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ANTI-VEGF, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ONCOLOGY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ONCOLOGY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ONCOLOGY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. GCC CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. GCC CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. GCC CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 183. GCC CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2032 (USD MILLION)
  • TABLE 184. GCC CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2032 (USD MILLION)
  • TABLE 185. GCC CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2032 (USD MILLION)
  • TABLE 186. GCC CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. GCC CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. GCC CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. G7 CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. G7 CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. G7 CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 210. G7 CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2032 (USD MILLION)
  • TABLE 211. G7 CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2032 (USD MILLION)
  • TABLE 212. G7 CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2032 (USD MILLION)
  • TABLE 213. G7 CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. G7 CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. G7 CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 216. NATO CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. NATO CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. NATO CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 219. NATO CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2032 (USD MILLION)
  • TABLE 220. NATO CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2032 (USD MILLION)
  • TABLE 221. NATO CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2032 (USD MILLION)
  • TABLE 222. NATO CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. NATO CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. NATO CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES CANCER BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA CANCER BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA CANCER BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA CANCER BIOLOGICS MARKET SIZE, BY ANTI-CD20, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA CANCER BIOLOGICS MARKET SIZE, BY ANTI-HER2, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA CANCER BIOLOGICS MARKET SIZE, BY ANTI-PD-1/PD-L1, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA CANCER BIOLOGICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA CANCER BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA CANCER BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)